Why Is Molina (MOH) Up 9.2% Since Last Earnings Report?

Molina Healthcare (MOH) reported mixed Q2 2025 results, with strong revenue growth of 15.7% to $11.4 billion, surpassing estimates, driven by premium increases. However, adjusted EPS of $5.48 marginally missed consensus and declined 6.5% year-over-year, primarily due to a higher Medical Care Ratio (MCR) of 90.4% and increased operating expenses. Consequently, the company significantly lowered its 2025 adjusted EPS guidance to at least $19 from its prior forecast of $24.50, leading to a substantial 35.62% downward revision in consensus estimates and a Zacks Rank #5 (Strong Sell), despite the stock's 9.2% gain since the last report.

Analysis

Molina Healthcare's recent 9.2% share price appreciation starkly contrasts with its deteriorating fundamentals reported in its second-quarter 2025 results. While the company posted strong top-line growth, with revenue rising 15.7% year-over-year to $11.4 billion and beating consensus by 5.4%, profitability was severely challenged. The primary issue was margin compression, evidenced by the Medical Care Ratio (MCR) climbing to 90.4% from 88.6% a year prior, exceeding both company and consensus estimates. This pressure drove a 6.5% year-over-year decline in adjusted EPS to $5.48 and a 13.8% drop in adjusted net income. The most significant development was the drastic reduction in full-year 2025 guidance, with adjusted EPS forecast slashed from 'at least $24.50' to 'at least $19'. This guidance cut has triggered a substantial 35.62% downward revision in consensus analyst estimates and a Zacks Rank #5 (Strong Sell), signaling a fundamental reset in earnings expectations. Further red flags include an increase in long-term debt and a significant rise in net cash used in operating activities, indicating weakening financial health.

Key Decisions for Investors

• Investors should view the recent 9.2% stock rally with extreme caution, as it is fundamentally disconnected from the severe downward revision of 2025 EPS guidance and rising medical cost pressures.
• The key metric to monitor is the Medical Care Ratio (MCR); any failure to stabilize it around the newly guided 90.2% level would signal further downside risk to earnings.
• Given the 35.62% collapse in consensus estimates and the 'Strong Sell' rating, long positions should be re-evaluated to account for the company's significantly weakened earnings profile and operational headwinds.
• While the stock's 'B' grade for value may attract some, the 'F' grades for growth and momentum suggest that any potential value is overshadowed by poor near-term prospects and negative sentiment.